

SPECIALTY QUANTITY LIMIT PROGRAM

SUTENT (sunitinib malate)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Sutent (sunitinib malate) capsule 12.5 mg	30 per 30 days	Gastrointestinal stromal tumor (GIST) and renal cell carcinoma (RCC): <ul style="list-style-type: none"> • 50 mg once daily, 4 weeks on treatment followed by 2 weeks off Pancreatic neuroendocrine tumors (pNET): <ul style="list-style-type: none"> • 37.5 mg once daily If co-administered with a CYP3A4 inducer, maximum recommended dose: <ul style="list-style-type: none"> • GIST and RCC: 87.5 mg once daily • pNET: 62.5 mg once daily
Sutent (sunitinib malate) capsule 25 mg	30 per 30 days	
Sutent (sunitinib malate) capsule 37.5 mg	30 per 30 days	
Sutent (sunitinib malate) capsule 50 mg	30 per 30 days	

III. REFERENCES

1. Sutent [package insert]. New York, NY: Pfizer Labs.; May 2019.